NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Propanc Biopharma, Inc. (PPCB) Stock Analysis

Propanc Biopharma, Inc. (PPCB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PPCB

$0.32

−$0.01 (−1.74%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PPCB with… →

PPCB Key Statistics

As of Oct 21, 2026
Trading
Open
$0.31
Previous Close
$0.32
Day's Range
0.31–0.32
52-Week Range
0.31–39.75
Volume
53.14K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.33
Valuation
Market Cap
$3.10M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−17.62
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$58.92M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
9.83M
1-Year Return
−99.21%
Dividend and dates
Avg Volume
1.84M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PPCB closed at $0.32, −99.21% over 1 year.

Propanc Biopharma, Inc. (PPCB) has a market capitalization of $3.10M.

In fiscal 2025, PPCB reported revenue of $0.00.

PPCB Stock Return by Calendar Year

Propanc Biopharma, Inc. (PPCB) return since Jan 2025: what $10,000 became

1 year
$10,000 $79
−99.21%
Since Jan 2025
$10,000 $210,267
+2,002.67%

If you had invested $10,000 in Propanc Biopharma, Inc. (PPCB) at the close on January 13, 2025, the earliest close on record here, it would have been worth $210,267 at the close on October 21, 2026: +2,002.67% in total, +459.63% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−97.65%
2025+89,333.33%

As of October 21, 2026.

PPCB Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$58.92M—
2024$0.00−$1.82M—
2023$0.00−$2.66M—
2022$0.00−$2.66M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$57.28M−$58.92M—
2024$0.00—−$1.54M−$1.82M—
2023$0.00—−$1.78M−$2.66M—
2022$0.00—−$1.99M−$2.66M—

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Propanc Biopharma, Inc. (PPCB) is capitalised at $3.10M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 2 employees.

Over the past 52 weeks the price has ranged from $0.31 to $39.75. PPCB last closed at $0.32 on October 21, 2026. That is −$0.01 (−1.74%) against the previous close. The latest close sits 2.5% above that 52-week low.

Financial Health

In fiscal 2025, Propanc Biopharma, Inc. reported revenue of $0.00. The same year closed with a net loss of $58.92M. Earnings per share on a trailing basis come to −17.62.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 3.33. Daily returns over the trailing 1 year annualize to a volatility of 182.57%. The trailing one-year total return is −99.21%. The stored price history starts on January 13, 2025, and the total return since then is +2,002.67%.

Growth & Income

No dividend is on file for PPCB.

The record holds one complete calendar year, 2025, which returned +89,333.33%. 2026 is still running; the total return is −97.65% year to date.

Peer Comparison

Propanc Biopharma, Inc. (PPCB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Propanc Biopharma, Inc. PPCB $3.10M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Propanc Biopharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Visit website →